Skip to main content
. 2016 Jul 11;12(3):2227–2231. doi: 10.3892/ol.2016.4842

Figure 5.

Figure 5.

PERK in the endoplasmic reticulum stress pathway is involved in MDA-MB-231 breast cancer cell invasion. (A) MDA-MB-231 cells were incubated with the indicated inhibitors (300 µM ATFi, 50 µM IRE1i and 10 µM PERKi) and used in the Matrigel-based invasion assay. The same number of cells was plated on a 24-well plate and used in the MTT assay to evaluate cell viability, which was used for normalization. The number of cells invading the Matrigel was normalized by setting the number of vehicle control cells invading the Matrigel to 100%. Representative invasion assay images are shown. Data are presented as the mean ± standard deviation. *P<0.005 for PERKi vs. vehicle. (B) shLuc and shPERK were transfected into MDA-MB-231 cells and used in the Matrigel-based invasion assay. The same number of cells was plated on a 24-well plate and used in the MTT assay to evaluate cell viability, which was used for normalization. The number of cells invading the Matrigel was normalized by setting the number of vehicle control cells invading the Matrigel to 100%. Representative invasion assay images are shown. Data are presented as the mean ± standard deviation. **P<0.001 vs. shLuc. ATF6i, activating transcription factor 6 inhibitor; PERKi, protein kinase RNA-like endoplasmic reticulum kinase inhibitor; IREi, inositol-requiring enzyme 1 inhibitor; shRNA, short hairpin RNA; shLuc, control shRNA; shPERK, shRNA targeting PERK mRNA.